MCM
MRTX

M28 Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

M28 Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-61,200
Closed -$4.27M – 17
2022
Q3 		$4.27M Hold
61,200
– – 4.46% 6
2022
Q2 		$4.11M Sell
61,200
-21,700
-26% -$1.38M 4.61% 7
2022
Q1 		$6.82M Buy
82,900
+63,700
+332% +$6.51M 6.27% 7
2021
Q4 		$2.82M Buy
+19,200
New +$2.98M 2.2% 11

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

M28 Capital Management's MRTX Position: Q4 2022 in Review

M28 Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2022, closing a stake of 61,200 shares — an estimated $4.27M sold.

M28 Capital Management first reported a position in MRTX in Q4 2021 and held it in 4 quarters. The position peaked at $6.82M in Q1 2022. 233 funds tracked by Wall St. Rank hold MRTX as of Q4 2022.

  • M28 Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • M28 Capital Management sold 61,200 Mirati Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $4.27M.
  • M28 Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
  • M28 Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $6.82M in Q1 2022.
  • 233 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2022.

Based on M28 Capital Management's 13F filing for Q4 2022, filed 10 Feb 2023.